about
Molecular inversion probes reveal patterns of 9p21 deletion and copy number aberrations in childhood leukemiaHDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombinationDNA Damage, Repair, and DiseasesPhase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancerPhase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancerSingle cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell linesp53 responsive nucleotide excision repair gene products p48 and XPC, but not p53, localize to sites of UV-irradiation-induced DNA damage, in vivoAmerican Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providersBreast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma.Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage.Opposing effects of the UV lesion repair protein XPA and UV bypass polymerase eta on ATR checkpoint signaling.Ductal pattern enhancement on magnetic resonance imaging of the breast due to ductal lavage.Poly (ADP-ribose) polymerase inhibitor, an effective radiosensitizer in lung and pancreatic cancers.The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk.Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessmentLinked read sequencing resolves complex genomic rearrangements in gastric cancer metastases.A Chimeric ATP-Linked Nucleotide Enables Luminescence Signaling of Damage Surveillance by MTH1, a Cancer Target.A clinical trial of lovastatin for modification of biomarkers associated with breast cancer risk.Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells.Sequencing of a QTL-rich region of the Theobroma cacao genome using pooled BACs and the identification of trait specific candidate genes.Clinical interpretation and implications of whole-genome sequencing.Metastatic tumor evolution and organoid modeling implicate TGFBR2 as a cancer driver in diffuse gastric cancer.Molecular inversion probe analysis of gene copy alterations reveals distinct categories of colorectal carcinomaPoly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer.p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene.Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatinIn vivo recruitment of XPC to UV-induced cyclobutane pyrimidine dimers by the DDB2 gene product.Identification of BRCA1/2 founder mutations in Southern Chinese breast cancer patients using gene sequencing and high resolution DNA melting analysis.Genomic DNA microarray analysis: identification of new genes regulated by light color in the cyanobacterium Fremyella diplosiphon.A kinase-independent function of c-Abl in promoting proteolytic destruction of damaged DNA binding proteins.A novel de novo BRCA1 mutation in a Chinese woman with early onset breast cancer.Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry.Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer.p53 and regulation of DNA damage recognition during nucleotide excision repair.Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repairBRCA1 and p53: compensatory roles in DNA repair.Functional characterization of global genomic DNA repair and its implications for cancer.Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countriesA rare case of an aldosterone secreting metastatic adrenocortical carcinoma and papillary thyroid carcinoma in a 31-year-old male.
P50
Q24657303-F8BAC6FF-177F-4F13-A7CB-737F2EADFE9EQ24670026-5732555B-6E98-4F78-BBD7-A37F8F1F3036Q24793635-E78F8187-B07B-44CB-BBC3-63D595B3E4E7Q27320322-8E513A0B-DAA3-471C-B15B-7175FF0645BFQ28272711-D9DE533E-EEFE-4071-B2A6-E6359B73F1B7Q28483475-9B535354-CA6A-4015-92B1-E3AF7A832591Q28609174-77605D31-9169-439A-B1F7-A6B00A9A9913Q30416965-0D297DEB-F1CE-4D22-BB9B-823D1696DFDAQ33197133-1C007C1F-1880-4600-8FAE-5B855BA83EC5Q33221678-C784C321-9D3D-456D-B1AE-AFE8CED98BCAQ33242349-CF2F7F6C-CAF2-41C8-AA26-2527386528D5Q33282899-77124740-0DB8-424D-8AFD-C3194C995A80Q33688658-23ADA90A-E950-48C5-8EA0-E39B89A42FD8Q33784408-F9F0FF02-9E8D-488F-ACF0-B4C3AAEA561AQ33796155-E7E945A8-3643-43BE-A7E0-5213B8D723E8Q33815218-E4DF49F8-0D89-4CDC-AA76-B1F739105ADEQ33880193-09E4200D-F8A6-4E78-9525-9374F020ED70Q33901385-853C3BEC-5A93-4987-A8D8-8FA56DECCF10Q33965570-E9277034-CA12-46F8-BCE2-A6C17650F5FDQ33972995-7DD4E731-64B3-4AB4-A678-E56BBC9E76B7Q33989890-D50FA16F-683F-48B2-8272-7EB22F5DFC5EQ34091425-7828B9A4-14AB-44E9-ABA1-7F288ACB474FQ34145288-B21671B9-0FFC-492C-BEC3-14FEFC9502F3Q34168535-D34E02C4-EA16-4BEF-B64F-25284E1613B8Q34191014-1F2116A3-FC96-4510-8AA2-0190C09EA641Q34204273-03C38739-C446-4BF3-A2CB-01EAACDED61CQ34226018-8C7DE02B-25E3-49D8-8678-02AA53F8DA82Q34412163-F4E95EA4-04F2-408C-897C-8F84BFDDBC06Q34435489-5A1581E8-D5EF-44EF-8674-2E35C39E3590Q34528552-E57EA581-5A3E-4F16-848B-96978715E6B0Q35000825-3C1ECBF5-3007-4BE6-B4EE-65E9686C9F01Q35146606-8855D129-69C6-458B-8208-5FA917C062C1Q35181103-4BE6E68C-7796-4327-8919-5FACDCBA234EQ35216363-18AED4A9-35DB-4EC8-A64B-56AF664021D4Q35251010-3F529AB9-64A8-4725-8E2C-EE3785D5E14CQ35298530-B52F806D-F8B2-47F8-A810-F3C448D0EF4AQ35596006-3BB9CA39-BF69-43C8-8103-0B0FC6287CC9Q35671356-80597D41-C3B7-496E-AA14-5007554A6FB8Q35695425-68134B9E-BE73-4B4F-B3AE-B12E064B71E5Q35765544-1B1E23D9-05BD-4BAD-9758-1301E5AA4372
P50
description
professor of medicine and researcher in oncology and genetics
@en
wetenschapper
@nl
name
James M Ford
@en
James M Ford
@nl
type
label
James M Ford
@en
James M Ford
@nl
altLabel
James Ford
@en
James Matthew Ford
@en
prefLabel
James M Ford
@en
James M Ford
@nl
P106
P214
P244
P21
P213
0000 0003 5054 9782
P214
P244
no2010155435
P31
P496
0000-0002-2513-7025